Skip to main navigation
Skip to search
Skip to main content
Penn State Home
Help & FAQ
Link opens in a new tab
Search content at Penn State
Home
Researchers
Research output
Research units
Equipment
Grants & Projects
Prizes
Activities
Impact of angiotensin system inhibitors on esophageal cancer survival
Xuanji Wang
, Patrick Sweigert
, Emanuel Eguia
, M. Alyssa Varsnik
, Christen R. Renz
, Weston A. Terrasse
, Madeline Gauthier
, Gerard Aranha
,
Lawrence M. Knab
, Gerard Abood
Department of Surgery
Research output
:
Contribution to journal
›
Article
›
peer-review
7
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Impact of angiotensin system inhibitors on esophageal cancer survival'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Esophageal Cancer
100%
Cancer-specific Survival
100%
Overall Survival
57%
Disease-free Survival
42%
Cancer Patients
28%
Esophagectomy
28%
Tumor
14%
Infection Rate
14%
Patient Demographics
14%
Relative Risk
14%
Adjuvant Therapy
14%
No Significant Difference
14%
Diabetes
14%
Retrospective Review
14%
Hypertension
14%
Patient Characteristics
14%
Neoadjuvant Therapy
14%
Renin-angiotensin System
14%
Adenocarcinoma Cells
14%
Surgical Approach
14%
Curative Surgery
14%
Therapy Approaches
14%
Cancer Types
14%
Kaplan-Meier
14%
Major Adverse Cardiovascular Events
14%
Esophageal Adenocarcinoma
14%
Cardiovascular Infections
14%
Squamous Cell Cancer
14%
Gastrointestinal Cancer
14%
Surgical Candidate
14%
Esophageal Pathology
14%
Improved Prognosis
14%
Esophageal Neoplasms
14%
Tumor Immune Microenvironment
14%
Cox Proportional Hazards Regression
14%
Tertiary Care Centers
14%
Single Institution
14%
Pathological Staging
14%
Medicine and Dentistry
Esophageal Cancer
100%
Angiotensin
100%
Overall Survival
57%
Disease Free Survival
42%
Esophagectomy
28%
Malignant Neoplasm
14%
Neoplasm
14%
Adjuvant Therapy
14%
Student T Test
14%
Diabetes
14%
Cancer Cell
14%
Cardiovascular Disease
14%
Infection Rate
14%
Cancer
14%
Neoadjuvant Therapy
14%
Proportional Hazards Model
14%
Tertiary Care
14%
Surgical Approach
14%
Squamous Cell
14%
Patient Characteristics
14%
Esophageal Adenocarcinoma
14%
Chronicity
14%
Tumor Immune Microenvironment
14%
Hepatobiliary Cancer
14%
Hypertension
14%